141 related articles for article (PubMed ID: 11396151)
1. Increased expression of peroxiredoxin II confers resistance to cisplatin.
Chung YM; Yoo YD; Park JK; Kim YT; Kim HJ
Anticancer Res; 2001; 21(2A):1129-33. PubMed ID: 11396151
[TBL] [Abstract][Full Text] [Related]
2. Peroxiredoxin I and II inhibit H2O2-induced cell death in MCF-7 cell lines.
Bae JY; Ahn SJ; Han W; Noh DY
J Cell Biochem; 2007 Jul; 101(4):1038-45. PubMed ID: 17163455
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of peroxiredoxin II antisense on cisplatin-induced cell death.
Yo YD; Chung YM; Park JK; Ahn CM; Kim SK; Kim HJ
Exp Mol Med; 2002 Sep; 34(4):273-7. PubMed ID: 12515392
[TBL] [Abstract][Full Text] [Related]
4. Antisense of human peroxiredoxin II enhances radiation-induced cell death.
Park SH; Chung YM; Lee YS; Kim HJ; Kim JS; Chae HZ; Yoo YD
Clin Cancer Res; 2000 Dec; 6(12):4915-20. PubMed ID: 11156252
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a cDNA of peroxiredoxin II responding to hydrogen peroxide and phagocytosis in Amoeba proteus.
Park M; Shin HJ; Lee SY; Ahn TI
J Eukaryot Microbiol; 2005; 52(3):223-30. PubMed ID: 15926998
[TBL] [Abstract][Full Text] [Related]
6. Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility.
Chan MM; Soprano KJ; Weinstein K; Fong D
J Cell Physiol; 2006 May; 207(2):389-96. PubMed ID: 16402374
[TBL] [Abstract][Full Text] [Related]
7. Oligomeric peroxiredoxin-I is an essential intermediate for p53 to activate MST1 kinase and apoptosis.
Morinaka A; Funato Y; Uesugi K; Miki H
Oncogene; 2011 Oct; 30(40):4208-18. PubMed ID: 21516123
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma.
Kinnula VL; Lehtonen S; Sormunen R; Kaarteenaho-Wiik R; Kang SW; Rhee SG; Soini Y
J Pathol; 2002 Mar; 196(3):316-23. PubMed ID: 11857495
[TBL] [Abstract][Full Text] [Related]
9. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
10. Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: a role of c-Jun NH2-terminal kinase 1.
Li F; Meng L; Zhou J; Xing H; Wang S; Xu G; Zhu H; Wang B; Chen G; Lu YP; Ma D
Biochem Biophys Res Commun; 2005 Oct; 335(4):1070-7. PubMed ID: 16105650
[TBL] [Abstract][Full Text] [Related]
11. T lymphocytes and dendritic cells are activated by the deletion of peroxiredoxin II (Prx II) gene.
Moon EY; Noh YW; Han YH; Kim SU; Kim JM; Yu DY; Lim JS
Immunol Lett; 2006 Feb; 102(2):184-90. PubMed ID: 16290204
[TBL] [Abstract][Full Text] [Related]
12. Elucidation of ATP-stimulated stress protein expression of RBA-2 type-2 astrocytes: ATP potentiate HSP60 and Cu/Zn SOD expression and stimulates pI shift of peroxiredoxin II.
Chen HB; Chan YT; Hung AC; Tsai YC; Sun SH
J Cell Biochem; 2006 Feb; 97(2):314-26. PubMed ID: 16178011
[TBL] [Abstract][Full Text] [Related]
13. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
14. Increased activator protein 1 activity as well as resistance to heat-induced radiosensitization, hydrogen peroxide, and cisplatin are inhibited by indomethacin in oxidative stress-resistant cells.
Bradbury CM; Locke JE; Wei SJ; Rene LM; Karimpour S; Hunt C; Spitz DR; Gius D
Cancer Res; 2001 Apr; 61(8):3486-92. PubMed ID: 11309312
[TBL] [Abstract][Full Text] [Related]
15. The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific.
Kissel CK; Schadendorf D; Röckmann H
Melanoma Res; 2006 Dec; 16(6):527-35. PubMed ID: 17119454
[TBL] [Abstract][Full Text] [Related]
16. Peroxiredoxin-4 interacts with and regulates the thromboxane A(2) receptor.
Giguère P; Turcotte ME; Hamelin E; Parent A; Brisson J; Laroche G; Labrecque P; Dupuis G; Parent JL
FEBS Lett; 2007 Aug; 581(20):3863-8. PubMed ID: 17644091
[TBL] [Abstract][Full Text] [Related]
17. Potential role of transforming growth factor beta1 in drug resistance of tumor cells.
Stoika R; Yakymovych M; Souchelnytskyi S; Yakymovych I
Acta Biochim Pol; 2003; 50(2):497-508. PubMed ID: 12833174
[TBL] [Abstract][Full Text] [Related]
18. Peroxiredoxin IV protects cells from radiation-induced apoptosis in head-and-neck squamous cell carcinoma.
Park JJ; Chang HW; Jeong EJ; Roh JL; Choi SH; Jeon SY; Ko GH; Kim SY
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1196-202. PubMed ID: 19251091
[TBL] [Abstract][Full Text] [Related]
19. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells.
Biliran H; Banerjee S; Thakur A; Sarkar FH; Bollig A; Ahmed F; Wu J; Sun Y; Liao JD
Clin Cancer Res; 2007 May; 13(9):2811-21. PubMed ID: 17473215
[TBL] [Abstract][Full Text] [Related]
20. Peroxiredoxins in breast carcinoma.
Karihtala P; Mäntyniemi A; Kang SW; Kinnula VL; Soini Y
Clin Cancer Res; 2003 Aug; 9(9):3418-24. PubMed ID: 12960131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
